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Calcium-dependent properties of CIB binding to the integrin αIIb
cytoplasmic domain and translocation to the platelet cytoskeleton
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The αIIbβ3 integrin receives signals in agonist-activated platelets,
resulting in its conversion to an active conformation that binds
fibrinogen, thereby mediating platelet aggregation. Fibrinogen
binding to αIIbβ3 subsequently induces a cascade of intracellular
signalling events. Themolecularmechanisms of this bi-directional
αIIbβ3-mediated signalling are unknown but may involve the
binding of proteins to the integrin cytoplasmic domains. We
reported previously the sequence of a novel 22-kDa, EF-hand-
containing, protein termed CIB (calcium- and integrin-binding
protein) that interacts specifically with the αIIb cytoplasmic
domain in the yeast two-hybrid system. Further analysis of
numerous tissues and cell lines indicated that CIB mRNA and
protein are widely expressed. In addition, isothermal titration
INTRODUCTION
The integrin αIIbβ3, or glycoprotein IIb-IIIa, is the major
integrin-adhesion receptor on platelets and mediates both platelet
aggregation and clot retraction. In unstimulated platelets the
majority of αIIbβ3 is present in a resting conformation or low-
affinity state, and is unable to bind circulating plasma fibrinogen.
However, upon platelet activation by agonists, αIIbβ3 receives
intracellular signals (inside-out signalling) that allow its rapid
conversion to a high-affinity state capable of binding soluble
ligands [1]. Once fibrinogen binds to αIIbβ3, this integrin
stimulates intracellular signalling (outside-in signalling), resulting
in cytoskeletal rearrangement and recruitment of signalling
molecules to the cytoskeleton, which are probably required for
processes such as clot retraction [2]. The mechanism of integrin-
mediated bi-directional signalling is unclear but molecular
approaches have demonstrated that the short cytoplasmic tails of
both the α and β subunits play an important role in both inside-
out [3–5] and outside-in signalling [6]. The αIIb and β3 cyto-
plasmic domains have been shown to interact with a number of
proteins, such as talin [7], Shc and Grb2 [8]. Moreover, a novel
110-amino acid protein termed β3-endonexin, which interacts
with the β3 cytoplasmic domain, was identified recently using the
yeast two-hybrid system [9], and found to convert αIIbβ3 to an
active state in Chinese hamster ovary cells [10].
We recently identified a novel 22-kDa calcium- and integrin-
binding protein, termed CIB, that interacts specifically with the
cytoplasmic domain of the integrin αIIb subunit [11]. CIB is
Abbreviations: CIB, calcium- and integrin-binding protein ; CaM, calmodulin ; ITC, isothermal titration calorimetry ; mAb, monoclonal antibody.
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calorimetry indicated that CIB binds to an αIIb cytoplasmic-
domain peptide in a Ca#+-dependent manner, with moderate
affinity (K
d
, 700 nM) and 1:1 stoichiometry. In aggregated
platelets, endogenous CIB and αIIbβ3 translocate to the Triton
X-100-insoluble cytoskeleton in a parallel manner, demonstrating
that the cellular localization of CIB is regulated, potentially by
αIIbβ3. Thus CIB may contribute to integrin-related functions
by mechanisms involving Ca#+-modulated binding to the αIIb
cytoplasmic domain and changes in intracellular distribution.
Key words: EF-hand motif, fibrinogen, intracellular signalling,
platelet activation, platelet aggregation.
expressed in platelets and binds to heterodimeric αIIbβ3 in itro.
CIB contains at least two EF-hand domains and is homologous
with other EF-hand containing proteins such as the regulatory
molecules, calcineurinB (58%homology) and calmodulin (CaM;
56% homology) [12,13].
Here we show that CIB mRNA and protein are widely
distributed in a variety of tissues. Moreover, CIB binds with
moderate affinity and in a calcium-dependent manner to the αIIb
cytoplasmic domain. In aggregated platelets, but not activated
platelets without aggregation, endogenous CIB and αIIb trans-
locate to the Triton X-100-insoluble cytoskeleton in a parallel
manner. These results suggest that CIB might influence aspects
of αIIbβ3 function in platelets, but may also have distinct roles
in cells that do not express this integrin.
EXPERIMENTAL
Peptide synthesis
Two N-terminally acetylated peptides corresponding to the C-
terminal 26 amino acids of αIIb [LVLAMWKVGFFKRNRP-
PLEEDDEEG(E}Q)], were synthesized and HPLC-purified by
The University of North Carolina at Chapel Hill}National
Institute of Environmental Health Sciences Protein Chemistry
Laboratory (Chapel Hill, NC, U.S.A.). Note that the peptides
terminated with either a C-terminal glutamic acid (peptide E), as
predicted by the cDNA sequence of αIIb [14], or a glutamine
(peptide Q), as predicted by Calvete et al. [15] based on analysis
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of platelet αIIb by MS. A truncated αIIb peptide with sequence
Ac-AMWKVGFFKRNRPPLEE (where Ac is acetyl) was
synthesized and HPLC-purified by the University of North
Carolina at Chapel Hill Department of Microbiology Protein
Sequencing and Peptide Synthesis Core Facility.
Antibodies
The affinity purified mouse monoclonal antibody (mAb) UN2
was raised against recombinant purified CIB and characterized
as described previously [11]. Affinity purified anti-αIIb polyclonal
antibody SEW8 was a generous gift from Dr. Peter Newman,
BloodCenter of SoutheasternWisconsin,Milwaukee,WI,U.S.A.
All other reagents were of analytical grade.
Northern-blot analysis
Human multiple-tissue Northern blots (Clontech, Palo Alto,
CA, U.S.A.) were probed with $#P-labelled CIB cDNA (5 ng}ml)
following the manufacturer’s protocol. Blots were subjected to
autoradiography overnight. The blots were stripped to remove
the initial probe and reprobed with β-actin cDNA to deter-
mine the relative amounts of the cDNA loaded in each lane,
which were similar.
Recombinant CIB
PCR was used to amplify the coding sequence for CIB and to
introduce 5« BglII and 3« EcoRI restriction sites. The purified
PCR product was digested with BglII and EcoRI, ligated into
pGEX-2T (Pharmacia, Piscataway, NJ, U.S.A.) between BamHI
and EcoRI sites, sequenced and subsequently expressed in
Escherichia coli as a fusion protein with glutathione S-transferase.
E. coli were grown at 37 °C and induced with 0.1 mM IPTG for
2.25 h. Cell pellets from 6 litres of E. coli culture were resuspended
in buffer A (1¬PBS, pH 7.5, 20 µg}ml leupeptin, 20 µg}ml
aprotonin, 1 mM PMSF and 5 mM dithiothreitol) and lysed
three times in a French press (1.1¬10) Pa). Cell lysate was
clarified by centrifugation, loaded on to a 25-ml glutathione-
Sepharose 4B column (Pharmacia), washed with 20 mM Tris}
HCl (pH 7.5)}137 mM NaCl and eluted with 25 ml of 10 mM
reduced glutathione in elution buffer (50 mM Tris}HCl, pH 8.0).
The eluate was incubated with bovine α-thrombin (Pharmacia;
10 units}mg of fusion protein) at ambient temperature for 2–4 h,
resulting in " 99% cleavage of fusion protein. CIB was further
purified by gel-exclusion chromatography using a HiPrep 16}60
S-200 column equilibrated in 20 mM Tris}HCl (pH 8.0)}150 mM
NaCl}1 mM EDTA}1 mM EGTA}10% glycerol, followed by
passage over glutathione-Sepharose 4B to remove residual
glutathione S-transferase. A final purification step was performed
on an 8-ml Resource Q column (Pharmacia) equilibrated with
20 mM Tris}HCl (pH 7.5)}10 mM NaCl}10% (v}v) glycerol.
The protein was eluted with a linear gradient of 0–500 mM
NaCl, concentrated by ultrafiltration (Amicon) with a YM-10
membrane, and stored at ®80 °C. CIB constituted " 99% of
total protein as determined on Commassie Brilliant Blue-stained
polyacrylamide gels. Recombinant CIB encodes the full-length
protein as well as an N-terminal dipeptide cloning artifact
(glycine-serine), previously part of the thrombin-recognition
sequence.
Isothermal titration calorimetry (ITC)
ITC was performed using an Omega Microcal calorimeter
(Microcal, Northhampton, MA, U.S.A.). CIB, lyophilized bov-
ine brain CaM (Calbiochem, San Diego, CA, U.S.A.) and αIIb
peptides were dialysed extensively against ITC buffer (20 mM
Hepes, pH 7.5, 137 mM NaCl and 5 mM CaCl
#
) prior to all
titrations. Concentrations of CIB (ε
#)!
, 2560 M−"[cm−"), CaM
(ε
#)!
, 2560 M−"[cm−") and αIIb peptides (ε
#)!
, 5690 M−"[cm−")
were determined as described previously [16]. CIB and αIIb
cytoplasmic-domain peptides were diluted to 50 µM and 2.1 mM
respectively with ITC buffer and used for titrations maintained
at 25 °C and consisting of 20 5-µl injections of peptide into CIB
at 300-s intervals. Similar titrations of ITC buffer into CIB, αIIb
peptides E and Q into ITC buffer and ITC buffer into ITC buffer
were performed to determine heats of dilution and mixing.
Titrations of peptide Q (1.25 mM) into CaM (50 µM) as a
negative control were performed as above for CIB. The enthalpy
of binding was determined as described in [17]. Binding isotherms
and curve fitting were obtained using Origin for ITC analysis
software (Microcal). For experiments without calcium, calcium
was removed from CIB by one of two procedures. First, the αIIb
peptide and CIB were dialysed for a minimum of 24 h against a
modified ITC buffer (20 mM Hepes, pH 7.5, 137 mM NaCl,
5 mM EDTA and 5 mM EGTA) supplemented with 1 g}100 ml
Chelex 100 resin (BioRad, Hercules, CA, U.S.A.). ITC titrations
were performed as described above. In the second procedure,
CIB was decalcified by three rounds of precipitation with 3%
trichloroacetic acid and refolded as described in detail by Haiech
et al. [18]. Each round of precipitation was followed by re-
suspension of CIB in 1 M Chelex-treated non-neutralized Tris
base except after the final precipitation when CIB was resus-
pended in 1 M Hepes}NaOH, pH 7.5. CIB was then dialysed
extensively against either the modified ITC buffer, which con-
tained Ca#+ chelators as described above, or ITC buffer, which
contained 5 mM Ca#+, and analysed for peptide-binding proper-
ties by ITC as above.
Preparation of washed platelets
Whole blood was drawn by venipucture from healthy aspirin-
free donors and collected in ACD (83 mM sodium citrate,
111 mM glucose, 71.4 mM citric acid, pH 4.5; 1 :7, v}v). Platelet-
rich plasma was isolated by centrifugation at 250 g for 20 min,
and prostaglandin E
"
(100 nM) or prostaglandin I
#
(50 ng}ml)
was added. The platelet-rich plasma was centrifuged for 15 min
at 850 g, and the platelets were resuspended in Hepes-buffered
saline (10 mM Hepes, pH 7.4, 138 mM NaCl, 12 mM NaHCO
$
,
10 mM KCl, 5.5 mM glucose, 0.35% BSA, 2 units}ml heparin
and 1 unit}ml apyrase). Resuspended platelets were washed three





added prior to each centrifugation (850 g,
10 min). The washed platelets were finally resuspended in buffer
A without BSA or inhibitors and the concentration was adjusted
to (0.5–1.0)¬10* platelets}ml. Platelets incubated for E 30 min
at 37 °C before use.
Platelet activation and cytoskeleton isolation
Washed platelets were stimulated with human thrombin (1 unit}
ml) under non-stirring or stirring conditions [1200 rev.}min
in a Chronolog aggregometer (Havertown, PA, U.S.A.)] at
37 °C. Stimulation of platelets with other agonists was per-
formed under stirring conditions only. Platelet cytoskeletons and
membrane skeletons were isolated as described by Fox et al. [19],
except that the low-speed centrifugation to isolate the cyto-
skeleton was for 6 min. Briefly, activated platelets were lysed
(1:1, v}v) by addition of 2¬lysis buffer (100 mM Tris}HCl, pH
7.5, 2% Triton X-100, 10 mM EGTA, 100 mM benzamidine,
2 mg}ml leupeptin and 1 mM Pefabloc SC). The lysate was
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centrifuged at E 15000 g for 6 min to obtain the actin cyto-
skeleton. In some experiments the supernatant was centrifuged
at 100000 g (Beckman TLA 100.2 rotor) for 2.5 h to obtain the
membrane skeleton. The supernatant following this centrifu-
gation was designated the Triton X-100-soluble fraction. All
fractions were solubilized in Laemmli sample buffer, separated
by SDS}PAGE [20], and electrotransferred to Immobilon-P
membranes [21]. Membranes were incubated in blocking buffer
[5% non-fat dried milk (Bio-Rad) in Tris-buffered saline (20 mM
Tris}HCl, pH 7.6, 137 mM NaCl) containing 0.1% Tween-20]
for 1–2 h and stained with UN2 or SEW8 in blocking buffer for
1 h. The membranes were incubated with sheep anti-mouse Fcγ
chain-specific IgG (Jackson) or donkey anti-rabbit IgG
(Amersham) conjugated with horseradish peroxidase and de-
veloped using enhanced chemiluminescence (ECL) as per the
manufacturers’ instructions. Immunoblots were analysed on a
GS670 densitometer (Bio-Rad).
RESULTS
Tissue expression of CIB
Since αIIbβ3 expression is largely restricted to platelets and
megakaryocytes, we asked whether CIB expression is restricted
to haematopoietic cells or more widely distributed. Probing of a
multiple-tissue Northern blot with CIB cDNA indicated a single
species of mRNA (0.9 kb) in all tissues examined, especially
pancreas and heart (Figure 1, top panel). Reprobing the Northern
blot with β-actin cDNA confirmed that differences in CIB
distribution could not be accounted for by differences in loading
(results not shown). We determined previously that CIB protein
is expressed in platelets [11]. Using platelets as a positive control,
we found by Western blotting that CIB protein is also expressed
in cell lines of megakaryocytic or erythrocytic lineages, i.e.
DAMI, Meg 01, K562 and HEL, and in the non-haematopoietic
T47D breast epithelial carcinoma cell line (Figure 1, bottom
panel). Previous lack of detection of message or protein in some
of these sources may have been due to less-optimized conditions
[11]. Thus mRNA encoding CIB and CIB protein appear to be
widely distributed.
ITC
We reported previously that CIB bound to the αIIb cytoplasmic
domain, as detected in the yeast two-hybrid system, and to the
intact αIIbβ3 integrin in an ELISA assay [11]. To gain more
quantitative information on this interaction, we examined CIB
binding to several αIIb cytoplasmic-domain peptides by ITC.
ITC detects the interaction of molecules in solution, without
separation of bound from unbound molecules as in some more
classical binding assays, thus allowing more accurate measure-
ment of affinity, stoichiometry and other physical characteristics
of binding [22].
CIB binding was measured to an αIIb cytoplasmic-domain
peptide with a C-terminal glutamine (peptide Q), as predicted by
MS of platelet αIIb, which suggests a post-translational (E!Q)
modification [15]. Results from ITC indicated that CIB binding
to this αIIb cytoplasmic-domain peptide was strongly favoured;
a K
d
of 700 nM and a stoichiometry of 1:1 (peptide}CIB) were
obtained. These values were confirmed by an independent
technique; changes in intrinsic fluorescence of the αIIb peptide
upon binding to CIB in solution indicated a similar K
d
and
stoichiometry (D. D. Shock, L. V. Parise and J. Sondek,
unpublished work). As measured by ITC, CIB also bound to an
αIIb peptide with a C-terminal glutamic acid (peptide E), with
slightly lower affinity (K
d
, 2 µM; results not shown). The
Figure 1 Expression of CIB in various human tissues and cell lines
(Top panel) A multiple-tissue Northern blot of 10 µg of total mRNA from the indicated human
tissues were probed with 32P-labelled CIB cDNA as described in the Experimental section.
(Bottom panel) Western blot of cell lysates. Platelets, as a positive control, or cell lines were
lysed in 1% Triton X-100 in PBS. Samples (25 µg) of the whole lysates were separated by
SDS/PAGE, transferred on to PVDF membranes and immunostained with the anti-CIB mAb,
UN2, as described in the Experimental section. Note that the left and right blots are from
separate experiments ; relative amounts of CIB can be compared within each blot but not
between blots. The 22-kDa CIB appears to migrate at E 25 kDa due to the aberrant migration
of the prestained molecular-mass markers.
interaction of CIB with the αIIb peptide is driven predominantly
by entropic factors and appears largely hydrophobic (see the
Discussion section). This is consistent with our inability to co-
immunoprecipitate CIB with αIIbβ3 from detergent-lysed
platelets (results not shown), since detergents would be expected
to disrupt hydrophobic interactions.
The specificity of this interaction is supported by the ob-
servation that, under similar conditions, the αIIb cytoplasmic-
domain peptide did not interact with the CIB homologue, purified
bovine brain CaM (Figure 2B, D). Specificity was further
confirmed by the observation that CIB also did not interact with
a truncated αIIb peptide consisting of residues 986–1002 (Figure
2B, y). This result suggests further that one or more of the
hydrophobic amino acids at the N-terminus of the cytoplasmic
domain and}or the charged residues at the C-terminus are
required for CIB binding.
In separate experiments, CIB binding to the αIIb cytoplasmic-
domain peptide was examined after removal of calcium by
exhaustive treatment with a series of calcium chelators or
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Figure 2 ITC of CIB binding to αIIb peptides
(A) Calorimetric trace of heat released upon titration of the cytoplasmic domain of the post-
translationally modified form of αIIb (Ac-LVLAMWKVGFFKRNRPPLEEDDEEGQ ; peptide Q) into
calcium-bound CIB. (B) Specificity of the αIIb cytoplasmic-domain peptide binding to CIB.
Titration of CIB with peptide Q (+) or a truncated αIIb cytoplasmic-domain peptide (Ac-
AMWKVGFFKRNRPPLEE ; y) were fitted to a one-site model. Values obtained for the binding
of peptide Q to CIB were as follows : Kd, 700 nM; ∆G, ®8.4 kcal/mol ; ∆H, ®3.3 kcal/mol ;
and ®T∆S, ®5.1 kcal/mol. The stoichiometry of binding was 1 :1 (peptide :CIB fitted ratio,
N, ¯ 1.15). D, indicate a titration of bovine CaM with peptide Q in the presence of 5 mM
CaCl2. These data do not realistically fit to any model and the heats generated were essentially
equivalent to the heats of dilution. (C) Inset shows a binding isotherm from αIIb cytoplasmic-
domain peptide E binding to calcium-depleted CIB.
following decalcification of CIB at low pH (see the Experimental
section). Upon calcium removal by either method, virtually
identical results were obtained; the affinity of CIB for the αIIb
peptide had decreased by at least two orders of magnitude and
the binding curve was no longer sigmoidal (Figure 2C). This
binding curve could no longer be accurately fitted to either a 1:1
or several other stoichiometric models of binding. These results
demonstrate that CIB interacts with the αIIb peptide in a largely
calcium-dependent manner.
Translocation of CIB and αIIbβ3 to the platelet cytoskeleton
We next asked whether CIB translocates to the low-speed Triton
X-100-insoluble actin cytoskeleton of activated or aggregated
platelets, as do many signalling molecules. The total amount of
Figure 3 Time course of CIB translocation from the Triton X-100-soluble
fraction to the insoluble actin cytoskeleton in thrombin-aggregated platelets
Washed platelets were aggregated with 1 unit/ml thrombin under stirring conditions for the
times indicated. The platelets were lysed in Triton X-100 and the insoluble actin cytoskeleton
(CSK, A) and the soluble fraction (B) were obtained following centrifugation (6 min, 15000 g).
Equivalent amounts of each fraction and whole platelet lysate (lane L), representing the total
amount of CIB were electrophoresed, transferred on to PVDF membranes, immunostained with
the anti-CIB mAb UN2, and detected by ECL as described in the Experimental section. (C) To
determine whether CIB translocation depended on fibrinogen-mediated platelet aggregation,
stirred platelets were pretreated for 5 min with either 200 µM RGDW or RGEW as a control,
prior to addition of 1 unit/ml thrombin for the times indicated. Cytoskeletons were obtained as
above and the blots were stained with UN2. (D) To determine whether the amount of
sedimentable actin cytoskeleton was related to the amount of CIB that sedimented, platelets
were aggregated by stirring with thrombin for 2 min as above and lysed with Triton X-100 lysis
buffer containing (­) or lacking (®) EGTA. EGTA omission allows actin filaments to be
severed by gelsolin. Cytoskeletal samples from equivalent numbers of platelets were
electrophoresed on either a 10% gel that was directly stained with Coomassie R-250 (left) or
a 14% gel that was transferred on to a PVDF membrane and immunostained with mAb UN2
(right).
CIB in the aliquots of platelet lysate used for experiments in
Figures 3(A) and 3(B) is shown in lanes labelled L. Before the
addition of thrombin, CIB was absent from the Triton X-100-
insoluble cytoskeleton (Figure 3A, time 0), but present in the
soluble fraction (Figure 3B, time 0). However, when platelets
were stirred with thrombin to induce platelet aggregation, there
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Figure 4 Comparison of CIB with αIIb cytoskeletal translocation in platelets aggregated by various agonists
Washed platelets (5¬108/ml) were stimulated with 1 µM A23187, 1 µM PMA, 2.5 µg/ml collagen or control vehicle (0.02% DMSO) for the indicated times. Platelets were lysed, and the actin
cytoskeleton (CSK) was sedimented by centrifugation for 6 min at E 15000 g. The pellets were solubilized in reducing SDS/PAGE sample buffer and subjected to electrophoresis on 4–20%
polyacrylamide gradient gels. Proteins were transferred on to PVDF membranes and immunostained with the anti-CIB mAb, UN2 (A), or the anti-αIIb polyclonal antibody, SEW8 (B). Note that
the patterns of CIB and αIIb translocation are similar.
was a significant increase in the amount of CIB that co-
sedimented with the cytoskeleton (Figure 3A, 10–300 s) and a
corresponding loss of CIB from the soluble fraction (Figure 3B,
10–300 s).
To determine whether the redistribution of CIB to the cyto-
skeleton was a function of ligand binding per se, or was dependent
on platelet aggregation, platelets were stirred in the presence of
thrombin and the RGDW peptide. This peptide was expected to
bind to αIIbβ3, block the binding of secreted fibrinogen and
block platelet aggregation. The RGDW peptide completely
blocked CIB translocation to the cytoskeleton except at the 300-
s time point (Figure 3C). However, by this time platelet micro-
aggregates were observed. In contrast, CIB translocation to the
cytoskeleton was not blocked by a control peptide (RGEW;
Figure 3C). We also found that CIB translocation was not
observed when platelets were activated by thrombin in the
absence of stirring, conditions that result in fibrinogen binding to
platelets but without aggregation (results not shown). Col-
lectively, these results suggest that platelet activation and ligand
occupancy of αIIbβ3 are insufficient to promote CIB trans-
location, and that platelet aggregation is required. In separate
experiments, we also examined the high-speed platelet-membrane
cytoskeleton, but found little CIB present in this fraction, whether
obtained from resting or activated platelets (results not shown).
Thus CIB translocates to the low-speed Triton X-100-insoluble
cytoskeletal fraction in thrombin-aggregated platelets.
If CIB co-sediments with the actin cytoskeleton because of an
attachment to it, procedures that decrease the amount of
sedimented actin should also decrease the amount of associated
CIB. To test this, cytoskeletal fractions were isolated from
thrombin-aggregated platelets in the presence of an EGTA-
containing lysis buffer as usual, or in a modified lysis buffer that
lacked EGTA (Figure 3D). EGTA is normally present to prevent
activation of the actin-severing protein, gelsolin, by Ca#+ that is
released during platelet lysis, whereas in the absence of EGTA,
activated gelsolin causes a decrease in actin-filament content of
the cytoskeleton [23]. We observed that, in the absence of EGTA,
36% less actin and 57% less CIB sedimented with the Triton X-
100-insoluble proteins (Figure 3D). These results suggest that
CIB sediments due to an attachment to the cytoskeleton, and not
because CIB becomes insoluble for other reasons.
It is well documented that αIIbβ3 translocates to the cyto-
skeleton upon platelet aggregation [19,24]. We therefore asked
whether the translocation of CIB paralleled that of αIIbβ3. This
was addressed by comparing a time course of CIB translocation
with that of αIIb in platelets that were stirred in the presence of
various agonists other than thrombin. Neither CIB nor αIIbβ3
translocated in significant amounts in the absence of an agonist
(DMSO; Figure 4). However, in platelets aggregated by the
calcium ionophore A23187, or collagen, both CIB (Figure 4A)
and αIIbβ3 (Figure 4B) translocated to the cytoskeleton within
1 min, whereas PMA caused a relatively delayed translocation of
both CIB and αIIbβ3. The similar patterns of αIIbβ3 and CIB
translocation to the cytoskeleton suggest that the translocation
of one may depend upon the other.
DISCUSSION
CIB was identified recently in the yeast two-hybrid system as a
22-kDa αIIb cytoplasmic-domain-binding protein that contains
at least 2 EF-hand motifs and binds Ca#+ [11]. It shows the
greatest homology with the regulatory molecules calcineurin B
and CaM, and KIP2, a molecule of unknown function [25]. In
the present study, we found that CIB protein and mRNA have
a wide tissue distribution. We have also demonstrated that the
binding of CIB to peptides mimicking the αIIb cytoplasmic
domain is highly favoured and most likely hydrophobic. Finally,
CIB translocates from a detergent-soluble to the Triton X-100-
insoluble cytoskeleton in aggregated platelets under conditions
that promote translocation of αIIbβ3. These results suggest that
CIB may serve as a docking and}or regulatory molecule in a
variety of cells, potentially at the cytoplasmic domain of αIIb
and in the cytoskeleton in platelets.
In the present study we observed that CIB mRNA and protein
are widely distributed. However, unlike CIB, the αIIbβ3 integrin
is restricted in distribution, being found only in platelets,
megakaryocytes and some transformed cells. CIB may therefore
be a widely distributed regulatory molecule with both αIIbβ3
integrin- and non-integrin-related functions.
ITC was used to determine the properties of CIB binding to
several αIIb cytoplasmic-domain peptides. In a strictly calcium-
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dependent manner, CIB binds to a peptide corresponding to the
entire cytoplasmic domain of αIIb with sub-micromolar affinity
(K
d
, 700 nM) and 1:1 stoichiometry. This interaction is specific,
since another EF-hand-containing protein, bovine brain CaM,
shows no detectable binding activity towards the αIIb peptide.
While this article was under review, a paper appeared by
Vallar et al. [26] claiming, in contrast to our results, that CIB
binds with " 10-fold lower affinity and in a Ca#+-independent
manner to the αIIb cytoplasmic domain [26]. The higher-affinity
interaction that we measured is likely to be more accurate due to
the fact that we used full-length CIB, not glutathione S-
transferase–CIB, and because this K
d
value falls well within a
range detected accurately by ITC (10−$–10−* M) [22]. Moreover,
we confirmed our measurements with the independent approach
of intrinsic protein fluorescence. Finally, surface plasmon res-
onance is subject to a large number of pitfalls not intrinsic to ITC
[27]. With regard to the Ca#+ dependency of CIB binding to the
αIIb cytoplasmic domain, the glutathione S-transferase–CIB
fusion protein used by Vallar et al. [26] may have been less
flexible or conformationally altered such that it was insensitive to
changes in Ca#+ levels as compared with CIB itself, which we
used. In addition, it is well documented that EF-hand-containing
proteins such as CIB can bind Ca#+ tightly such that simple
incubation with EDTA, as indicated by Vallar et al. [26], is often
insufficient to remove Ca#+ from these proteins [18]. We found
that CIB treated for calcium removal with two methods accepted
in the EF-hand field (i.e. dialysis for " 24 h against EDTA,
EGTA and Chelex, or trichloroacetic acid precipitation and
refolding [18]) gave identical results ; the affinity of CIB binding
to the αIIb cytoplasmic domain was decreased by well over two
orders of magnitude following Ca#+ removal.
The contacts between model peptides and CaM observed in
crystal structures [28] were used to guide the synthesis of a
truncated αIIb peptide that would potentially retain binding
activity towards CIB. This peptide lacked three N-terminal and
six C-terminal amino acids. We found that this peptide had no
observable affinity for CIB, suggesting that one or more of the
truncated amino acids were critical for high-affinity interaction
of αIIb and CIB. However, this finding further substantiates the
specificity of the interaction between CIB and the complete αIIb
cytoplasmic-domain peptide.
The ITC data also indicate that CIB binding to the αIIb
cytoplasmic domain is driven primarily by increased system
entropy. The homology of CIB with CaM (E 56%) and other
EF-hand-domain-containing proteins suggests that CIB may
bind effector peptides in a manner similar to EF-hand proteins.
Calcium binding causes substantial conformational changes in
many EF-hand proteins, leading to the exposure of large
hydrophobic surfaces involved in peptide binding [29]. By
analogy, large hydrophobic portions of CIB and αIIb cyto-
plasmic-domain peptide presumably interact, leading to the
expulsion of structured water from the peptide–protein interface
into bulk solvent. Upon complex formation, displaced water
would contribute greatly to overall system entropy, outweighing
any entropic costs associated with less-mobile peptide or protein.
This would account for the thermodynamics of the reaction in a
process classically referred to as the hydrophobic effect [30]. If so,
this is consistent with the fact that we have been unable to co-
immunoprecipitate CIB with αIIbβ3, despite the use of multiple
detergents and buffer conditions, since hydrophobic interactions
would be disrupted by detergent.
Interestingly, a similar analysis of CaM binding to a peptide
from smooth-muscle myosin light-chain kinase indicated the
opposite thermodynamic behaviour [31]. CaM bound to
the peptide with a large favourable enthalpy and negligible or
unfavourable entropy. This behaviour is consistent with the
decreased mobility of both CaM and the peptide upon complex
formation. It is also consistent with the numerous van-der-Waals
and electrostatic interactions within the complex, as observed in
the crystal structure [28]. The differences in thermodynamics of
peptide binding to CIB versus CaM probably reflect underlying
structural differences. CaM possesses inherent flexibility that
allows it to bind numerous peptide effectors with high comple-
mentarity and affinity [29]. In an unbound state, CIB may be less
mobile than CaM. Upon complex formation, the interface
between CIB and αIIb may be less complementary than similar
CaM–peptide complexes. This binding behaviour would also
suggest that CIB may bind fewer target effectors than CaM.
Consistent with its putative role as a calcium-dependent
regulatory protein, the affinity of CIB binding to the αIIb peptide
in the absence of calcium was at least two orders of magnitude
lower than that of calcium-bound CIB. Moreover, the binding
could no longer be fitted to a peptide:CIB ratio of 1:1, 2 :1 or
several other stoichiometric models of binding. The low-affinity
binding that remains after calcium removal could represent bind-
ing that occurs only with calcium-stripped CIB, binding that
occurs due to a low but residual amount of calcium or, less likely,
a calcium-independent component that is also present with
calcium-replete CIB, and is probably not physiologically relevant.
Thus CIB binding to the αIIb cytoplasmic domain is largely
calcium-dependent and potentially modulated by changes in
intracellular calcium.
CIB exhibits a dramatic and almost complete translocation to
the cytoskeleton of agonist-aggregated platelets, but not of
activated platelets without aggregation. These results suggest
that CIB would not be expected to translocate to the cytoskeleton
of agonist-activated platelets from patients with Glansmann’s
thrombasthenia, since these platelets do not aggregate. In
normal platelets, a variety of signalling molecules also translocate
to the cytoskeletal fraction of aggregated platelets, including
phospholipase C [32], Tec [33], kinases such as p160
ROCK (Rho-associated coiled-coil-containing kinase) [34] and
phosphatidylinositol 3-kinase [35], andprotein phosphatases such
as PP1 and PP2a [36]. Translocation of many of these molecules
also appears to depend upon αIIbβ3 occupancy and platelet
aggregation. Following CIB translocation in aggregated platelets,
the platelets are lysed in Triton X-100. The fact that this
association is maintained in the presence of detergent suggests a
non-hydrophobic mechanism of association, unlike that with
αIIbβ3, which might make it possible for CIB to co-associate
with the cytoskeleton and the integrin. Whether CIB serves to
carry or attach the integrin to the cytoskeleton or whether CIB
is required for this translocation is possible but unknown. It is
equally possible that CIB and αIIbβ3 translocate to the cyto-
skeleton without direct physical association with one another.
One notion of cytoskeleton function is as a solid state for the
surface chemistry of signalling reactions. The presence of CIB
in the cytoskeleton suggests that it is available to regulate some of
the multiple kinases, phosphatases or other signalling molecules
that also become associated with the cytoskeleton. This ob-
servation is consistentwith deposits inGenBank and the literature
indicating the identification of proteins with sequences virtually
identical to CIB that bind to serum-inducible kinase or SNK [37]
(accession no. U83236) and DNA-dependent protein kinase
[38]. However, Western blotting of a CIB immunoprecipitate
with an anti-DNA-dependent protein kinase antibody was nega-
tive. (J. E. Brittain, U. P. Naik and L. V. Parise, unpublished
work). Thus the exact role of CIB in cells awaits the further
definition of intracellular proteins that interact with this potential
regulatory molecule.
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